Seeking a nonhormonal discussion is different from arriving with a medicine already selected. Myla Health offers private menopause appointments in the UK, with time to discuss symptoms and their impact. Its public information also explains what happens after a visit, including letters, prescription administration and the limits of responsibility for tests obtained elsewhere.
This review uses Myla’s service, pricing and FAQ records checked September 29, 2026. They verify clinical consultation access, but not a guaranteed menu of named systemic nonhormonal medicines. The relevant question is what the clinician would recommend for the actual concern, under UK practice and prescribing conditions, rather than which US product approval can be attached to the clinic.
A symptom discussion comes before an assumed prescription
Myla's service description says an initial consultation lasts approximately 45 minutes and considers symptoms and their effect on daily life. Appointments may be in person or by video. The page describes a proposed treatment discussion, not automatic dispensing when someone books.
Use the visit-goals guide to distinguish the reason for avoiding hormones from the problem needing help. Those could be different parts of the history. Myla's hormone-focused examples do not prove that a particular nonhormonal medicine is available. Ask explicitly whether the appointment can address that request before treating a general menopause service as a verified product pathway.
The place of the appointment is a real access condition
The Myla FAQ says patients must be on UK soil at the time of the appointment and need a UK address for medication delivery. A video format does not erase those requirements or create a US prescribing service. The location of the patient matters alongside the location of the clinician.
The Newson Clinic review examines another UK care model, with its own published consultation scope and charges. Comparing those appointment records can clarify practical questions without assuming that either clinic offers an identically named medicine or follows the approval conditions of a US label discussed elsewhere on this publication.
A private recommendation does not compel NHS prescribing
Myla's FAQ explains that the clinic issues private prescriptions and can write to an NHS GP with recommendations. It explicitly notes that local formularies and prescribing policies differ and the GP is not obliged to prescribe at Myla's request. A letter is therefore a communication step, not a completed transfer of responsibility.
For a nonhormonal proposal, ask who will continue prescribing if the GP declines and what that would cost. The medicine-family guide supplies clinical background, not evidence of UK availability. Neither a medicine's presence in that guide nor a private clinician's recommendation establishes that a particular NHS practice will provide it.
Outside tests have a narrower responsibility boundary
The patient FAQ permits records and investigation results to be uploaded, but does not guarantee advance review. It says clinicians take responsibility for investigations they request or formally review and interpret, and excludes automatic responsibility for tests arranged by others. Urgent results should be taken to the professional who requested the investigation.
That matters if an existing prescription or another specialist already involves testing. Our fezolinetant monitoring guide illustrates the type of coordination question to ask; it is not evidence Myla prescribes that medicine. Establish who receives, interprets and acts on results rather than assume that uploading a report completes clinical review.
Appointment fees and cancellation rules should travel together
Myla's April 2026 price schedule lists £290 for an initial 45-minute appointment and £190 for a 30-minute follow-up. Private prescription administration after the first three months costs £35; actual medication is charged separately by the pharmacy. Those units should remain beside the prices when comparing clinics.
The FAQ requires payment when booking. Cancellation with less than 24 hours' notice incurs the full fee; more than 24 hours but less than two working days incurs 50%. Another line says cancellation more than 48 hours ahead is free. Because working days and clock hours can differ, confirm the applicable deadline rather than silently treating those formulations as identical.
Follow-up email has a defined, limited role
The service page describes emails for clarification and brief side-effect questions while settling into care, with more complex concerns requiring a follow-up appointment. That is a useful distinction between communication access and a further assessment. It should not be read as an unlimited consultation entitlement or emergency service.
The FAQ requires an annual 30-minute review if Myla continues prescribing. After more than 18 months since the last visit, it asks for a new 45-minute appointment. These are published service requirements, not a personal medicine schedule. Ask how those requirements would apply to the actual nonhormonal plan and any involvement from another clinician. Our Allara review concerns a US program with a different payment and care model; its monthly access language cannot define what is included in a Myla appointment.
Evidence for an approach remains separate from the clinic offer
The 2023 nonhormone evidence review supports particular treatments for vasomotor symptoms, including structured behavioral approaches. It does not establish which interventions Myla offers, what training a specific practitioner has for them or which medicine is appropriate for an individual. Clinical evidence and service availability require separate support.
A useful appointment should leave the intended symptom outcome, proposed intervention and follow-up responsibility understandable. Myla's published records support investigating that conversation within its stated UK boundaries. They do not support a promise of a named prescription, automatic NHS adoption, a specific outcome or a complete treatment price before the actual plan is known.
Follow the evidence
Source documents
Read each source for the product, population and purpose it describes. Commercial pages document advertised terms, not individual care outcomes.
- Myla Health: consultation servicesUK private clinical service; NHS prescribing remains separate · Checked 2026-09-29
- Myla Health: patient FAQsUK location, billing, cancellation and investigation responsibility conditions · Checked 2026-09-29
- Myla Health: prices effective April 1, 2026UK visit and prescription-administration fees, excluding actual medicine · Checked 2026-09-29
- The Menopause Society: 2023 nonhormone therapy position statementProfessional evidence review; predates Lynkuet approval · Checked 2026-09-29